4//SEC Filing
KYTHERA BIOPHARMACEUTICALS INC 4
Accession 0001104659-15-068855
CIK 0001436304operating
Filed
Oct 1, 8:00 PM ET
Accepted
Oct 2, 2:15 PM ET
Size
12.6 KB
Accession
0001104659-15-068855
Insider Transaction Report
Form 4
Rich Douglas A.
Vice President Operations
Transactions
- Disposition to Issuer
Common Stock
2015-10-01−2,044→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−20,000→ 0 totalExercise: $47.63Exp: 2025-05-26→ Common Stock (20,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−40,000→ 0 totalExercise: $32.61Exp: 2024-04-30→ Common Stock (40,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−28,217→ 0 totalExercise: $38.53Exp: 2025-01-29→ Common Stock (28,217 underlying)
Footnotes (5)
- [F1]Disposed of pursuant to the Amended and Restated Agreement and Plan of Merger dated as of August 4, 2015 (the "Merger Agreement" and the transactions contemplated therein, the "Merger"), by and among Allergan plc (formerly known as Actavis plc) ("Allergan"), Keto Merger Sub, Inc. (a wholly owned subsidiary of Allergan) and Issuer, whereby each share of Issuer common stock was canceled in exchange for $75.00 in cash, without interest.
- [F2]Includes 369 shares acquired under the Issuer's 2015 Employee Stock Purchase Plan on September 21, 2015.
- [F3]Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 10,572 shares of Allergan common stock at an exercise price of $123.38 per share.
- [F4]Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 7,457 shares of Allergan common stock at an exercise price of $145.78 per share.
- [F5]Pursuant to the Merger Agreement, this option was assumed by Allergan in the Merger on the same terms and conditions regarding vesting and exercisability, and automatically converted into an option to purchase 5,286 shares of Allergan common stock at an exercise price of $180.21 per share.
Documents
Issuer
KYTHERA BIOPHARMACEUTICALS INC
CIK 0001436304
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001436304
Filing Metadata
- Form type
- 4
- Filed
- Oct 1, 8:00 PM ET
- Accepted
- Oct 2, 2:15 PM ET
- Size
- 12.6 KB